Core Viewpoint - Health Catalyst (HCAT) has experienced a significant downtrend, with a 21.4% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 indicating that a stock may be oversold [2]. - HCAT's current RSI reading is 28.93, indicating that the heavy selling pressure may be exhausting, which could lead to a price rebound [5]. - RSI helps investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling [3]. Group 2: Fundamental Indicators - Analysts covering HCAT have raised earnings estimates for the current year, resulting in a 128.1% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - HCAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating strong potential for a near-term turnaround [8].

Core Viewpoint - Certara, Inc. (NASDAQ:CERT) is identified as an oversold value stock with significant upside potential, supported by analyst confidence and recent upgrades despite sector volatility [1][2][3][4]. Group 1: Analyst Sentiment - As of February 5, 2026, 60% of analysts maintain a bullish outlook on Certara, with a consensus price target of $12.00, indicating a 57.70% upside potential [2]. - KeyBanc reduced its price target from $13 to $12 but reiterated an 'Overweight' rating, citing fundamental momentum and a year of inflection for Certara despite industry challenges [3]. - Leerink upgraded Certara from 'Market Perform' to 'Outperform' while keeping the price target at $13, attributing this to the company's leadership in the biosimulation market and viewing the previous selloff as an overreaction [4]. Group 2: Company Overview - Certara focuses on providing software and technology-enabled services for drug developers, including modeling, decision analytics, clinical pharmacology, complex biologics, and regulatory strategy solutions [5].

Core Viewpoint - The article discusses 14 oversold value stocks that present investment opportunities due to significant price declines and favorable analyst sentiment, amidst a broader market context of volatility and potential recovery [5][7]. Market Overview - U.S. equity markets are expected to remain strong in 2026, with a target for the S&P 500 set at 7,700 based on technical indicators rather than fundamentals [2]. - Market breadth is improving, with smaller stocks like the Russell 2000 breaking through resistance levels [3]. - Morgan Stanley projects a 14% rise in the S&P 500 over the next 12 months, driven by earnings growth, anticipated Federal Reserve rate cuts, and corporate tax reductions [3]. Recent Market Activity - A sharp selloff occurred in the business software sector, with the S&P 500 software and services index declining for seven consecutive sessions, now trading 21% below its 200-day moving average, marking the deepest drop since June 2022 [4][5]. - This selloff has pushed several value stocks into oversold territory, creating potential investment opportunities [5]. Methodology for Stock Selection - The selection of the 14 oversold value stocks was based on criteria including a forward P/E below 16, a three-month share price decline of 20%-40%, and a Relative Strength Index below 40 [7]. - Stocks were also evaluated for their potential to rebound, with significant analyst coverage considered [7]. Hedge Fund Sentiment - Stocks were ranked based on the number of hedge funds holding each stock as of Q3 2025, indicating bullish sentiment from institutional investors [8]. - Research suggests that imitating top hedge fund stock picks can lead to market outperformance [9]. Individual Stock Highlights - **eToro Group Ltd. (NASDAQ:ETOR)**: Experienced a 22.94% decline over three months, with a 103.5% upside potential and strong analyst sentiment [10]. Analysts from Goldman Sachs, Mizuho, and TD Cowen have adjusted price targets, reflecting mixed views on the stock's future [11][12][13]. - **Certara, Inc. (NASDAQ:CERT)**: Noted a 34.11% decline over three months, with a 57.70% upside potential and 60% analyst bullishness [15]. Analysts from KeyBanc and Leerink have provided insights on the stock's performance and future growth prospects [16][17]. - **Enovis Corporation (NYSE:ENOV)**: Faced a 27.31% decline over three months, with a 97.30% upside potential [19]. Analysts from Evercore ISI and BTIG have reiterated positive ratings, highlighting the company's revenue dynamics and market strategy [20][22].

Core Insights - HeartSciences Inc. has partnered with the University of the West of England to establish a Reference Center for ECG Education and Technology, utilizing its MyoVista Insights™ platform and MyoVista® wavECG™ device as exclusive ECG technologies [1][2][3] Group 1: Partnership and Technology Adoption - The MyoVista Insights and MyoVista wavECG device will be exclusively used in UWE's cardiac and physiological science teaching programs, aimed at training future cardiac scientists [2] - This partnership supports NHS England workforce priorities and enhances the UK's cardiac diagnostic capacity [2][3] Group 2: Educational Impact - The establishment of the UWE ECG Education and Technology Reference Center will serve as a nationally aligned academic reference site, facilitating clinical adoption discussions with NHS trusts and providing real-world validation of MyoVista Insights™ [3] - The MyoVista Insights platform is noted for advancing ECG analysis beyond traditional methods, enhancing student engagement and understanding of cardiac electrophysiology [4] Group 3: Strategic Positioning - The collaboration reinforces HeartSciences' long-term commercial positioning within the UK healthcare ecosystem, creating a strategically important reference site for broader engagement with the NHS [3][4] - The CEO of HeartSciences expressed satisfaction with the partnership, highlighting its significance for clinical and educational value [4]

Core Insights - KLAS Research has recognized Wolters Kluwer Sentri7 clinical surveillance as the Best in KLAS for Pharmacy Surveillance and Infection Control & Monitoring [1] Company Summary - Wolters Kluwer Sentri7 has achieved top rankings in two critical areas: Pharmacy Surveillance and Infection Control & Monitoring, indicating its strong performance and reliability in clinical surveillance [1]

Core Viewpoint - HeartSciences Inc. has partnered with Cibolo Rural Health Networks to provide its MyoVista Insights™ ECG management platform to a network of 123 independent hospitals, enhancing ECG workflow efficiency and clinical decision-making [1][2][4]. Group 1: Company Overview - HeartSciences is a healthcare information technology company focused on advancing electrocardiography through artificial intelligence integration [1][5]. - The MyoVista Insights platform is a cloud-native ECG management system designed to improve clinical efficiency and decision-making [5]. Group 2: Partnership Details - Cibolo Health has selected MyoVista Insights as its endorsed ECG management platform for its network of independent hospitals across six states [2][4]. - The collaboration aims to modernize legacy ECG workflows, allowing physicians to interpret ECGs more quickly and efficiently [2][4]. Group 3: Technology and Benefits - MyoVista Insights provides secure, cloud-based ECG data management across various devices and file formats, supporting the integration of AI-ECG algorithms into clinical practice [3]. - The partnership aligns with Cibolo Health's mission to enhance care quality and operational efficiency while managing costs for its member hospitals [4][6].

As filed with the Securities and Exchange Commission on January 8, 2026 Registration No. 333-______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SCWORX CORP. (Exact Name of Registrant As Specified In Its Charter) Delaware 7374 47-5412331 (State Or Other Jurisdiction Of Incorporation Or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 35 VILLAGE RD., SUITE ...

Core Viewpoint - HeartSciences Inc. is advancing its MyoVista Insights™ healthcare IT platform and has submitted its MyoVista® wavECG™ device for FDA clearance, marking significant progress in the commercialization of its ECG technology [1][2][5]. Group 1: Business Developments - The Company has made substantial advancements in the commercialization of its MyoVista Insights™ platform and has submitted the MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance [2][5]. - MyoVista Insights is classified as a Medical Device Data System (MDDS), which allows for a faster and less costly commercial rollout compared to regulated medical devices [7]. - The platform has received strong validation from early adopters and is currently in commercial discussions with several healthcare institutions, with expectations to announce key customer wins soon [5][7]. Group 2: Financial Results - HeartSciences reported no meaningful revenue for the fiscal second quarter ended October 31, 2025, and had approximately $2.0 million in cash and cash equivalents, along with $4.2 million in shareholders' equity [8]. Group 3: Market Opportunity - The MyoVista Insights platform is designed to host third-party AI-ECG algorithms, positioning the Company to capture a multibillion-dollar market opportunity while reducing costs and time for algorithm development and regulatory clearance [7]. - The Company plans to host an investor call early in the new year to demonstrate the MyoVista Insights software and discuss its commercialization strategy and market opportunity [7].

Core Insights - HeartSciences Inc. has submitted its MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance, marking a significant regulatory milestone in its commercialization strategy [1][2] Company Overview - HeartSciences is a healthcare information technology company focused on enhancing ECG/EKG usage through artificial intelligence integration [3] - The MyoVista Insights platform is a next-generation ECG management system designed to improve clinical efficiency and decision-making [3] Product Details - The MyoVista wavECG device offers conventional ECG functionality and is capable of hosting AI-ECG algorithms [2] - The company has opted to separate the FDA submissions for the MyoVista wavECG device and its AI-ECG software algorithm to align with updated clinical standards and expedite the regulatory review process [2] Strategic Developments - The separation of submissions is intended to simplify the regulatory pathway and accelerate device clearance while allowing for future deployment of the AI-ECG algorithm across multiple platforms [2] - The company is making progress with its MyoVista Insights platform and is engaged in commercial discussions with healthcare institutions, expecting to announce initial customer deployments soon [2]

Core Insights - Nationwide access to validated Oregon POLST forms is now enabled by MyDirectives and HIT Commons in participating EHR workflows [1] Group 1 - MyDirectives and HIT Commons have collaborated to provide access to Oregon POLST forms across the nation [1] - The integration allows for improved workflows within electronic health records (EHR) systems [1]